BIOVIE INC (BIVI)

Company Profile

BioVie Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Carson City, Nevada and currently employs 14 full-time employees. The company went IPO on 2014-01-14. BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Company Info

BIOVIE INC

680 W Nye Lane, Suite 201

Carson City NEVADA 90404

P: 17758883162

CEO: Cuong Do

Employees: 14

Website: https://www.bioviepharma.com/